Walter Klemp V - 11 Jul 2022 Form 4/A - Amendment Insider Report for Moleculin Biotech, Inc. (MBRX)

Role
CEO and President, Director
Signature
/s/ Jonathan P. Foster by Power
Issuer symbol
MBRX
Transactions as of
11 Jul 2022
Net transactions value
-$5,401
Form type
4/A - Amendment
Filing time
15 Jul 2022, 20:03:45 UTC
Date Of Original Report
13 Jul 2022
Previous filing
15 Jul 2022
Next filing
18 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MBRX Common Stock Options Exercise +13,204 +5.9% 235,650 11 Jul 2022 Direct F1
transaction MBRX Common Stock Tax liability $5,401 -3,215 -1.4% $1.68 232,435 11 Jul 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBRX Restricted Stock Units Options Exercise $0 -13,205 -1.2% $0.000000 1,097,941 11 Jul 2022 Common Stock 13,204 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
F3 On July 11, 2019, the reporting person was granted 52,818 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Remarks:

Filed solely to correct the amount in Table II, Column 9, from 1,369,941 to 1,097,941.